Cargando…

The future role of personalized medicine in the treatment of glioblastoma multiforme

Glioblastoma multiforme (GBM) remains one of the most malignant primary central nervous system tumors. Personalized therapeutic approaches have not become standard of care for GBM, but science is fast approaching this goal. GBM’s heterogeneous genomic landscape and resistance to radiotherapy and che...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Di, Chunhui, Mattox, Austin K, Wu, Linda, Adamson, D Cory
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513213/
https://www.ncbi.nlm.nih.gov/pubmed/23226047
http://dx.doi.org/10.2147/PGPM.S6852
_version_ 1782251902469144576
author Li, Jing
Di, Chunhui
Mattox, Austin K
Wu, Linda
Adamson, D Cory
author_facet Li, Jing
Di, Chunhui
Mattox, Austin K
Wu, Linda
Adamson, D Cory
author_sort Li, Jing
collection PubMed
description Glioblastoma multiforme (GBM) remains one of the most malignant primary central nervous system tumors. Personalized therapeutic approaches have not become standard of care for GBM, but science is fast approaching this goal. GBM’s heterogeneous genomic landscape and resistance to radiotherapy and chemotherapy make this tumor one of the most challenging to treat. Recent advances in genome-wide studies and genetic profiling show that there is unlikely to be a single genetic or cellular event that can be effectively targeted in all patients. Instead, future therapies will likely require personalization for each patient’s tumor genotype or proteomic profile. Over the past year, many investigations specifically focused simultaneously on strategies to target oncogenic pathways, angiogenesis, tumor immunology, epigenomic events, glioma stem cells (GSCs), and the highly migratory glioma cell population. Combination therapy targeting multiple pathways is becoming a fast growing area of research, and many studies put special attention on small molecule inhibitors. Because GBM is a highly vascular tumor, therapy that directs monoclonal antibodies or small molecule tyrosine kinase inhibitors toward angiogenic factors is also an area of focus for the development of new therapies. Passive, active, and adoptive immunotherapies have been explored by many studies recently, and epigenetic regulation of gene expression with microRNAs is also becoming an important area of study. GSCs can be useful targets to stop tumor recurrence and proliferation, and recent research has found key molecules that regulate GBM cell migration that can be targeted by therapy. Current standard of care for GBM remains nonspecific; however, pharmacogenomic studies are underway to pave the way for patient-specific therapies that are based on the unique aberrant pathways in individual patients. In conclusion, recent studies in GBM have found many diverse molecular targets possible for therapy. The next obstacle in treating this fatal tumor is ascertaining which molecules in each patient should be targeted and how best to target them, so that we can move our current nonspecific therapies toward the realm of personalized medicine.
format Online
Article
Text
id pubmed-3513213
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-35132132012-12-05 The future role of personalized medicine in the treatment of glioblastoma multiforme Li, Jing Di, Chunhui Mattox, Austin K Wu, Linda Adamson, D Cory Pharmgenomics Pers Med Review Glioblastoma multiforme (GBM) remains one of the most malignant primary central nervous system tumors. Personalized therapeutic approaches have not become standard of care for GBM, but science is fast approaching this goal. GBM’s heterogeneous genomic landscape and resistance to radiotherapy and chemotherapy make this tumor one of the most challenging to treat. Recent advances in genome-wide studies and genetic profiling show that there is unlikely to be a single genetic or cellular event that can be effectively targeted in all patients. Instead, future therapies will likely require personalization for each patient’s tumor genotype or proteomic profile. Over the past year, many investigations specifically focused simultaneously on strategies to target oncogenic pathways, angiogenesis, tumor immunology, epigenomic events, glioma stem cells (GSCs), and the highly migratory glioma cell population. Combination therapy targeting multiple pathways is becoming a fast growing area of research, and many studies put special attention on small molecule inhibitors. Because GBM is a highly vascular tumor, therapy that directs monoclonal antibodies or small molecule tyrosine kinase inhibitors toward angiogenic factors is also an area of focus for the development of new therapies. Passive, active, and adoptive immunotherapies have been explored by many studies recently, and epigenetic regulation of gene expression with microRNAs is also becoming an important area of study. GSCs can be useful targets to stop tumor recurrence and proliferation, and recent research has found key molecules that regulate GBM cell migration that can be targeted by therapy. Current standard of care for GBM remains nonspecific; however, pharmacogenomic studies are underway to pave the way for patient-specific therapies that are based on the unique aberrant pathways in individual patients. In conclusion, recent studies in GBM have found many diverse molecular targets possible for therapy. The next obstacle in treating this fatal tumor is ascertaining which molecules in each patient should be targeted and how best to target them, so that we can move our current nonspecific therapies toward the realm of personalized medicine. Dove Medical Press 2010-08-19 /pmc/articles/PMC3513213/ /pubmed/23226047 http://dx.doi.org/10.2147/PGPM.S6852 Text en © 2010 Li et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Li, Jing
Di, Chunhui
Mattox, Austin K
Wu, Linda
Adamson, D Cory
The future role of personalized medicine in the treatment of glioblastoma multiforme
title The future role of personalized medicine in the treatment of glioblastoma multiforme
title_full The future role of personalized medicine in the treatment of glioblastoma multiforme
title_fullStr The future role of personalized medicine in the treatment of glioblastoma multiforme
title_full_unstemmed The future role of personalized medicine in the treatment of glioblastoma multiforme
title_short The future role of personalized medicine in the treatment of glioblastoma multiforme
title_sort future role of personalized medicine in the treatment of glioblastoma multiforme
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3513213/
https://www.ncbi.nlm.nih.gov/pubmed/23226047
http://dx.doi.org/10.2147/PGPM.S6852
work_keys_str_mv AT lijing thefutureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT dichunhui thefutureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT mattoxaustink thefutureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT wulinda thefutureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT adamsondcory thefutureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT lijing futureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT dichunhui futureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT mattoxaustink futureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT wulinda futureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme
AT adamsondcory futureroleofpersonalizedmedicineinthetreatmentofglioblastomamultiforme